title: Radiofrequency ablation of drug-refractory atrial fibrillation: an observational study comparing 'ablate and pace' with pulmonary vein isolation.
abstract: OBJECTIVE
  To compare clinical characteristics, procedure complexity, acute and long-term outcome of 'ablate and pace' (A&P) with pulmonary vein isolation (PVI) in patients with drug-refractory atrial fibrillation (AF). So far, only few small studies have compared the two procedures.
  
  
  RESULTS
  We analysed retrospectively a cohort of symptomatic consecutive patients with drug-refractory AF. Group 1 included 100 patients treated with A&P and Group 2 included 144 patients treated with PVI. Group 1 patients were older (74 +/- 8 vs. 56 +/- 9 years; P < 0.0001), had lower left ventricular ejection fraction (50 +/- 13% vs. 59 +/- 7%; P < 0.05), and a lower prevalence of paroxysmal AF (46% vs. 65%; P < 0.05). Acute success was not statistically different (98% vs. 92.3%, P = ns). Group 1 patients had shorter procedure time and lower radiation exposure with respect to Group 2 patients (70 +/- 15 vs. 204 +/- 58 min, and 8 +/- 4 vs. 57 +/- 22 min; P < 0.0001, respectively). After a median follow-up of 29 months (I, III quartile; 15, 40 months) vs. 25 months (I, III quartile; 8, 36 months) (P = ns), all the patients in Group 1 were free of symptomatic AF, while 113 patients (79%) of Group 2 were in stable sinus rhythm (P < 0.0001). Persistent or permanent AF has been documented in 58 patients (58%) of Group 1 vs. 11 (8%) of Group 2 (P < 0.0001).
  
  
  CONCLUSIONS
  In this series (i) patients treated with A&P and PVI for drug-refractory AF showed significant differences in clinical profile; (ii) A&P is a shorter and less complex procedure, but is associated with a higher rate of persistent AF; (iii) symptomatic recurrences of paroxysmal AF were more frequent in PVI group. Randomized studies appear necessary to identify the best strategy in selected cases.
authors.affiliation: Department of Cardiology, Azienda Ospedaliera-Universitaria and IRCAB Foundation, P.le S. Maria della Misericordia 15, 33100 Udine, Italy. ap.ircab@gmail.com
authors.forename: Alessandro
authors.initials: A
authors.lastname: Proclemer
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Allocca
authors.forename: Dario
authors.initials: D
authors.lastname: Gregori
authors.forename: Carlo
authors.initials: C
authors.lastname: Bonanno
authors.forename: Renato
authors.initials: R
authors.lastname: Ometto
authors.forename: Alessandro
authors.initials: A
authors.lastname: Fontanelli
authors.forename: Roberto
authors.initials: R
authors.lastname: Mantovan
authors.forename: Martino
authors.initials: M
authors.lastname: Crosato
authors.forename: Vittorio
authors.initials: V
authors.lastname: Calzolari
authors.forename: Daisy
authors.initials: D
authors.lastname: Pavoni
authors.forename: Domenico
authors.initials: D
authors.lastname: Facchin
authors.forename: Luca
authors.initials: L
authors.lastname: Rebellato
authors.forename: Paolo M
authors.initials: PM
authors.lastname: Fioretti
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000601:surgery*; D002304:Cardiac Pacing, Artificial / Q000379:methods*; D017115:Catheter Ablation / Q000379:methods*; D003131:Combined Modality Therapy; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011667:Pulmonary Veins / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents